MoonLake Immunotherapeutics (MLTX) Interest & Investment Income (2021 - 2022)
MoonLake Immunotherapeutics (MLTX) posted quarterly Interest & Investment Income of $8431.0 for Q1 2022, down 52.67% year-over-year from $17815.0 in Q1 2021, and up 273.88% quarter-over-quarter from $2255.0 in Q4 2021.
Powered by 
Analysis
MoonLake Immunotherapeutics (MLTX) Interest & Investment Income (2021 - 2022) Analysis & Trends
MoonLake Immunotherapeutics' Interest & Investment Income history runs 2 years deep, the most recent figure standing at $8431.0 for Q1 2022.
- In Q1 2022, Interest & Investment Income fell 52.67% year-over-year to $8431.0; the TTM figure through Mar 2022 stood at $18307.0 (changed N/A YoY), while the FY2021 annual figure was $27691.0, up 85.63% from the prior year.
- Interest & Investment Income for Q1 2022 stood at $8431.0, up from $2255.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $17815.0 in Q1 2021, with the low at $1481.0 in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 10.98 Mn |
| 10 | MoonLake Immunotherapeutics | 1.10 Bn | 565.05 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2022 | 8,431.00 |
| Dec 31, 2021 | 2,255.00 |
| Sep 30, 2021 | 1,481.00 |
| Jun 30, 2021 | 6,140.00 |
| Mar 31, 2021 | 17,815.00 |